Condition: Oncolytic Virus · Diffuse Intrinsic Pontine Glioma · Adverse Drug Event · Sponsor: Capital Medical University
This is a drug safety assessment clinical trial with a 3+3 dose escalation design, to observe the safety, tolerability and toxicity of a novel oncolytic virus Ad-TD-nsIL12 intratumoral injection in primary DIPG patients (NCI-CTCAE V5.0).
This description comes directly from the study's public registry record.
Xiao Qian, Dr. · 18020295435 · ryan521q@sina.com
Always discuss trial participation with your own doctor first.
| Sanbo Brain Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05717712